^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Comp 3
i
Other names: Comp 3
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Joyant Pharma
Drug class:
IAP antagonist
Related drugs:
almost4years
Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. (PubMed, Cell Death Dis)
In addition, Comp34 alone is effective in cells with secondary resistance to rapamycin, the best-known inhibitor of mTOR, and displays a greater in vivo antitumor efficacy and lower toxicity than rapamycin in TNBC xenografted models. In conclusion, NUDT3-AS4 may play a proproliferative role in TNBC and be considered a relevant therapeutic target, and Comp34 presents promising activity as a single agent to inhibit TNBC through regulation of NUDT3-AS4 and miR-99s.
Preclinical • Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
sirolimus • Comp 3
Share via
